临床肝胆病杂志2017，Vol.33Issue(6)：1063-1066,4.DOI:10.3969/j.issn.1001-5256.2017.06.009
直接抗病毒药物联合PR方案(PEG-IFN联合利巴韦林)在丙型肝炎抗病毒治疗新时代的价值
Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C
摘要
Abstract
Pegylated interferon (PEG-IFN) combined with ribavirin (PR regimen) has been used in China for more than 10 years.With the development of direct-acting antiviral agents (DAAs),the therapeutic regimens for hepatitis C has become more and more diverse.In the regimen of DAAs combined with PR regimen,IFN helps to benefit the long-term prognosis of patients with chronic hepatitis C (CHC),and the addition of DAAs may improve therapeutic effect,shorten the course of treatment,and further improve the current status of treatment of CHC.This article introduces the advantages and disadvantages of PR regimen,DAAs combined with PR regimen,and oral regimen with DAAs,in order to investigate the therapeutic regimens suitable for different CHC patients and provide a reference for clinical practice.关键词
肝炎,丙型,慢性/抗病毒药/治疗Key words
hepatitis C, chronic/antiviral agents/therapy分类
医药卫生引用本文复制引用
陈新月,柳雅立,任姗..直接抗病毒药物联合PR方案(PEG-IFN联合利巴韦林)在丙型肝炎抗病毒治疗新时代的价值[J].临床肝胆病杂志,2017,33(6):1063-1066,4.基金项目
首都临床特色应用研究(Z151100004015181,Z161100000516018) （Z151100004015181,Z161100000516018）
首都卫生发展科研重点专项(首发2016-1-218-3) （首发2016-1-218-3）
